Ingredients for success: A familial cancer clinic in an oncology practice setting

Journal of Oncology Practice

Volumn 7, Issue 1, 2011, Pages 39-42

  Duncan, By Paul R ^a   Lin, James T ^a  

^a VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CENTER; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; COMMUNITY CARE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OVARY CANCER; POLYPOSIS;

EID: 79955686119     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000048     Document Type: Article

References (31)

1. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 14:1730-1736, 1996
2. American Society of Clinical Oncology policy update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
3. Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for genetic susceptibility. J Clin Oncol 28:893-901, 2010
4. MacDonald DJ, Blazer KR, Weitzel JN: Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: The power of partnership. J Natl Compr Canc Netw 8:615-624,2010
5. Geier LJ, Mulvey TM, Weitzel JN: Clinical cancer genetics remains a specialized area: How do I get there from here? Presented at the 2009 Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 29-June 2, 2009
6. Hematology Oncology Associates. http://www.hoanm.com
7. Hampel H, Sweet K, Westman JA, et al: Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet 41:81-91, 2004 (Pubitemid 38221744)
8. Garber J, Zon R, Weitzel J: Genetic counseling: An indispensable step in the genetic testing process. J Oncol Pract 4:96-98, 2008 (Pubitemid 351586696)
9. Offit K: Clinical Cancer Genetics: Risk Counseling and Management. New York, NY, Wiley-Liss, 1998
10. Offit K, Thom P: Ethical and legal aspects of cancer genetic testing. Semin Oncol 34:435-443, 2007 (Pubitemid 47503275)
11. Goldgar DE, Easton DF, Byrnes GB, et al: Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29:1265-1272, 2008
12. Lindor NM, McMaster ML, Lindor CJ, et al: Concise handbook of familial cancer susceptibility: Second edition. J Natl Cancer Inst Monogr 38:1-93, 2008
13. Metcalfe KA, Finch A, Poli A, et al: Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100:421-425, 2009
14. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
15. Dent R, Warner E: Screening for hereditary breast cancer. Semin Oncol 34:392-400, 2007 (Pubitemid 47503270)
16. Duncan PR: Identification of the BRCA1 187delAG mutant allele in New Mexico Hispanic families with hereditary breast and ovarian cancer (HBOC). J Clin Oncol 23:858s, 2005 (suppl; abstr 9588)
17. Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331-1337, 2008
18. Weitzel JN, McCaffrey SM, Nedelcu R, et al: Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138: 1323-1328, 2003
19. Silva E: Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: Perspective of a surgical oncologist. Fam Cancer 7:91-95, 2008
20. Pierce LJ, Levin AM, Rebbeck TR, et al: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443, 2006 (Pubitemid 46630619)
21. Daly MB, Axilbund JE, Buys S, et al: Genetic/familial high-risk assessment: Breast and ovarian-clinical practice guidelines in oncology. J Natl Compr Cancer Netw 8:562-594, 2010
22. Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41:664-668, 2004 (Pubitemid 39208606)
23. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med: 352:1851-1860, 2005
24. Terdiman JP: It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology 129:741-744, 2005 (Pubitemid 41096657)
25. Evans DG, Walsh S, Hill J, et al: Strategies for identifying hereditary nonpolyposis colon cancer. Semin Oncol 34:411-417, 2007 (Pubitemid 47503269)
26. Duncan PR, Lin JT, Feddersen R: Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. J Clin Oncol 28:162s, 2010 (suppl; abstr 1535)
27. Lindor NM: Hereditary colorectal cancer: MYH-associated polyposis and other newly identified disorders. Best Pract Res Clin Gastroenterol 23:75-87, 2009
28. DeMarco TA, Smith KL, Nusbaum RH, et al: Practical aspects of delivering hereditary cancer risk counseling. Semin Oncol 34:369-378, 2007 (Pubitemid 47503271)
29. University of Kansas Medical Center: Clinical genetics computer resources. http://www.kumc.edu/gec/prof/genecomp.html
30. de Jong AE, Hendriks YMC, Kleibeuker JH, et al: Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665-671, 2006 (Pubitemid 43374516)
31. Lindor NM, Petersen GM, Hadley DW, et al: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome. JAMA 296:1507-1517, 2006 (Pubitemid 44465515)